Abstract: A process for the manufacture of a multilayer structure suitable for forming part of an organic electronic device having a cathode and an anode wherein liquid compositions with solvent systems comprising organic compounds with ionizable groups are deposited out of solution.

Abstract: The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.

Abstract: Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

Abstract: The present invention relates to a host material comprising a compound having two carbazole moieties which is suitable for blue-emitting OLEDs. Surprisingly, it has been found that when appropriate substituents are present in the carbazole structure, the solubility of the compounds can be improved without any adverse effect on the OLED performance. The present invention further relates to the use of the host materials and to an organic light emitting device comprising the host material.

Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.

Abstract: Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.

Abstract: Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.

Abstract: The present invention relates to the use of liquid-crystal displays (LCDs), and to processes for the recycling thereof. The processes according to the invention are characterised in that the LCDs are employed at least partly as replacement for other raw materials. In general, the LCDs are thermally treated here at a temperature in the range from 900 to 1700° C.

Abstract: The present invention relates to the use of liquid-crystal displays (LCDs), and to processes for the recycling thereof. The processes according to the invention are characterised in that the LCDs are employed at least partly as replacement for other raw materials. In general, the LCDs are thermally treated here at a temperature in the range from 900 to 1700° C.

Abstract: The present invention relates to the use of liquid-crystal displays (LCDs), and to processes for the recycling thereof. The processes according to the invention are characterised in that the LCDs are employed at least partly as replacement for other raw materials. In general, the LCDs are thermally treated here at a temperature in the range from 900 to 1700° C.

Abstract: The present invention relates to a host material comprising a compound having a carbazole moiety which is suitable for blue-emitting OLEDs. Surprisingly, it has been found that when appropriate substituents are present in the carbazole structure, the solubility of the compounds can be improved without any adverse effect on the OLED performance. The present invention further relates to the use of the host materials and to an organic light emitting device comprising the host material.

Abstract: The present invention relates to a host material comprising a compound having two carbazole moieties which is suitable for blue-emitting OLEDs. Surprisingly, it has been found that when appropriate substituents are present in the carbazole structure, the solubility of the compounds can be improved without any adverse effect on the OLED performance. The present invention further relates to the use of the host materials and to an organic light emitting device comprising the host material.

Abstract: The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.

Abstract: A composite gland sealing for the interlocking coupling of a housing end piece (8) including an anchoring groove (82), a plastic ring (14) and several locking inserts (20). Each locking insert (20) includes a radially external head (30) provided with a first front projection (50, 52) applicable against the annular front surface (90) of the anchoring groove (82). The head (30) comprises includes a second frontal projection (52, 50) radially shifted from the first front projection (50, 52).

Abstract: A polymer composition comprising (a) a polybenzimidazole derived from (a1) at least one bis-(ortho-diamino) aromatic compound and (a2) at least one aromatic carboxylic acid or derivative thereof, each containing at least two acid groups and at least one hydroxyl group in ?-position of a carboxylic group; (b) orthophosphoric acid; and (c) polyphosphoric acids of the formula (I): HO[P(O)(OH)]nH, wherein n is an integer from 2 to 20, wherein the polyphosphoric acids of formula (I) are present in an amount of less than 2 mol %, based upon the sum of moles of orthophosphoric acid (b) and polyphosphoric acids (c), and wherein (b) is present in an amount of 1 to 75 moles per mol of a benzimidazole group formed from (a1) and (a2). A polymer membrane comprising the polymer composition, a preferred process for preparing the membrane, and a fuel cell comprising the membrane.

Abstract: The invention concerns a polybenzazole block copolymer suitable for solid polymer electrolyte membranes application comprising: at least one block (B1) comprising recurring units (R), more than 50% of said recurring units comprising at least one benzimidazole group (formula 1a and 1b) and at least one sulfonic acid group (formula 2) [recurring units (R1)]; ?wherein E in formula 1a can be a substituted or non-substituted carbon atom or nitrogen atom, and Q in formula 1 can be a hydrogen atom or a group comprising a sulfonic acid group; and at least one block (B2) comprising recurring units (R?), more than 50% by moles of said recurring units comprising at least one benzazole group chosen among benzoxazole group (formula 3a and 3b) and benzothiazole group (formula 4a and 4b) [recurring units (R2)], ?wherein E? and E? in formula 3a and 4a, respectively, can be a substituted or non-substituted carbon atom or nitrogen atom, and the block (B2) is free from sulfonic acid groups.

Abstract: The present invention provides solid alkaline fuel cells comprising anion exchange membranes which comprise diamines or polyamines coupled to a support polymer via a sulfonamide linkage. At least one nitrogen atom of the diamine or polyamine is a quaternized nitrogen atom acting as an anion exchange group. The anion exchange membrane exhibits favourable properties that render it suitable for use in a solid alkaline fuel cell.

Abstract: A process for preparing a halogenated polymer in a medium comprising liquid or supercritical carbon dioxide, comprising a step involving the radical polymerization of at least one halogenated monomer and at least one step involving cross-flow filtration; and a cross-flow filtration device.

Abstract: The present invention is related to complex peptide mixtures with immunomodulatory effects and methods for their use. The invention is further directed toward treatments of diseases through the modulation of the immune system with complex peptide mixtures. The invention is also directed to methods for improving the characteristics of complex peptide mixtures.